OBJECTIVE
The objective of this analysis was to assess the cost effectiveness of LAAC versus warfarin for stroke prevention in non-valvular atrial fibrillation from the perspective of the US Centers for Medicare & Medicaid Services (CMS).
BACKGROUND
Medicare spends an estimated $16 billion annually to manage beneficiaries with atrial fibrillation (AF), and nearly half of this spend is on AF-related stroke. 1 AF affects almost 9% of all Medicare beneficiaries putting them at a 5 times greater risk of stroke. 2, 3 Stroke is considered the most severe and debilitating consequence of AF, with many patients ranking the resultant disability worse than death. 4 To fully understand the burden of stroke, stroke severity and the resultant impact on patient quality of life (QoL) need also be considered.
Warfarin has been the long established treatment for stroke prevention in AF; it is effective at reducing the risk of ischemic stroke, but leads to increased risk of bleeding, reduced overall quality of life, and poor patient compliance. [4] [5] [6] [7] The WATCHMAN is a device for percutaneous closure of the left atrial appendage Left atrial appendage closure (LAAC) with the WATCHMAN Device has been found to be superior to warfarin at reducing the composite risk of stroke, systemic embolism and cardiovascular death in nonvalvular AF patients. 8 LAAC with the WATCHMAN Device was recently approved by the FDA to reduce the risk of thromboembolism from the LAA in patients with non-valvular AF who are at increased risk for stroke, warfarin suitable, and seeking a non-pharmacologic alternative to warfarin.
In light of ever increasing cost pressures, healthcare policy makers are increasingly in need of evidence of value in addition to evidence of clinical efficacy.
Other analyses have evaluated the cost effectiveness of LAAC for stroke risk reduction in AF, but none have incorporated PROTECT AF stroke severity and QoL data, variables which impact both cost effectiveness and patient therapy acceptance.
METHODS

•
A Markov model was developed to assess the cost effectiveness of LAAC with the WATCHMAN Device relative to warfarin for stroke risk reduction in non-valvular AF from a CMS perspective over a 20-year time horizon.
The model was populated with data from a cohort of 10,000 70-year old patients with a mean CHADS 2 score of 2 and a bleeding risk reflective of the PROTECT AF population. 8 
Clinical event probabilities and QoL data were obtained from the PROTECT AF trial at 4 years of follow up. 8 Table 1 . Clinical probabilities
• As the US reimbursement specific to this procedure is being reevaluated, a separate sensitivity analysis examined the impact of procedure cost with values up to $26,000.
• Patients who were not successfully implanted with the WATCHMAN Device were assumed to remain on warfarin therapy; otherwise there was no LAAC treatment discontinuation.
• Compliance with warfarin therapy was assumed to be equal to that observed in the PROTECT AF 4-year ITT data; no additional discontinuation was assumed. Table 2 . PROTECT AF stroke outcomes and utility scores
• The Nichol ordinary least squares algorithm was used to convert the SF-12 data into utility scores, with 0 representing death and 1 representing perfect health. 11 • Utility scores for well LAAC and warfarin patients were set to 0.999 and 0.977, respectively.
• New stroke outcomes data from PROTECT AF were incorporated to capture the impact of stroke severity on QoL and cost outcomes.
• Previously developed utilities for stroke severity were taken from the literature. 4 • Inpatient cost data were taken from US DRG reimbursement rates, acute rehabilitation costs from inpatient rehabilitation facility reimbursement rates, and outpatient costs from CPT ® reimbursement rates. 12,13,15 • Data on the long-term costs of disability from stroke were taken from the literature and applied in each 3-month model cycle for the duration of the patient's life. 16 
Incremental QALYs
• Clinical events included ischemic stroke, hemorrhagic stroke, systemic embolism, major bleeding, and all-cause mortality.
• Model outcomes are presented as total cumulative cost, incremental cost per life year gained and incremental cost per quality-adjusted life year (QALY) gained.
• The cost-effectiveness threshold was set to the commonly accepted U.S. willingness-to-pay value of $50,000 per life year or QALY gained.
• Sensitivity analyses were conducted on clinical variables and LAAC procedure cost by varying inputs across 95% confidence intervals where available and +/-20% where not available.
• SF-12 data for PROTECT AF patients who did not have a stroke were used to inform the QoL utilities for well patients treated with either LAAC or warfarin. 9, 10 • In a cohort of 10,000 AF patients, LAAC avoided 1,352 strokes over the 20-year time horizon, representing a 35% reduction relative to warfarin.
• LAAC patients, on average, lived 1.1 quality-adjusted life years longer than their warfarin counterparts.
• By year 10, mean cumulative patient costs were lower for LAAC than warfarin ($24,516 versus $24,739, respectively).
• Over a lifetime, LAAC saved an average of $13,069 per patient relative to warfarin.
• LAAC was cost effective (less than $50,000 per QALY) compared to warfarin by year 6 and dominant (less expensive and more effective) to warfarin by year 10.
• In a probabilistic sensitivity analysis, LAAC resulted in greater life expectancy at 10 years (8.26 years, 95% CI: 8.16 to 8.34) than warfarin (7.88 years, 95% CI: 7.64 to 8.1) in 100% of simulations.
• LAAC was cost saving relative to warfarin in 55% of simulations at 10 years.
• The mean 10-year cost per QALY was $2,208 (95% CI: -$10,514 to $33,090). Probability of cost effectiveness at 10 years was greater than 99% given a willingness-to-pay threshold of $50,000 per QALY.
• In a secondary sensitivity analysis using $26,000 for procedure cost, LAAC remained cost effective over both lifetime ($8,305 per QALY) and 10-year ($41,198 per QALY) time horizons despite increased procedure costs. 
Limitations
CONCLUSIONS
• Four-year results from the PROTECT AF trial found LAAC to be superior to warfarin for reduction of stroke/systemic embolism/cardiovascular death.
• This analysis indicates that LAAC with the WATCHMAN Device is cost effective compared to warfarin at 6 years and less expensive than warfarin at 10 years.
• LAAC remains cost effective relative to warfarin even when procedure costs are increased substantially.
• LAAC with the WATCHMAN Device for stroke prevention in AF provides improved clinical and quality of life outcomes and offers better value to CMS over a patient's lifetime.
• The results of this analysis should be considered when formulating policy and practice guidelines for stroke prevention in AF. 
